Experience of 2<sup>nd</sup> line therapy with eltrombopag in patients with immune thrombocytopenia

Background. Immune thrombocytopenia (ITP), or idiopathic thrombocytopenic purpura, is a hematological autoimmune disease characterized by bleeding and an isolated decrease in platelet count <100 × 10 9 / l. The decision to start treatment for ITP depends on several factors. strategy based the clinical symptoms, with focus reducing risk of severe increasing counts. Aim. To evaluate efficacy 2 nd line therapy thrombopoietin receptor agonist eltrombopag patients ITP. Materials methods. 490 are under observation at center orphan diseases M. F. Vladimirskiy Moscow Regional Research Clinical Institute. present study included 186 primary after 1 st glucocorticosteroid therapy. eltrombopag, agonist, was prescribed as Results. median prior all 27.5 therapy, significant (by %) increase levels (median 135 l) complete response according recommendations were noted. Conclusion. Glucocorticosteroids (prednisolone, dexamethasone) remain drugs choice Treatment this group most cases allows achieving optimal level preventing bleeding. In case inefficiency, intolerance, occurrence side effects, appointment agonists romiplostim recommended. dose 50 mg daily weeks has been able achieve levels, correct hemorrhagic syndrome, reduce number effects during first-line improve patient’s quality life.